souseikai global clinical research center

Our Sites’ Operational Statuses (As of May 26th, 2020)

While ensuring the safety of trial subjects, employees, and client partners, we remain focused and committed to maintaining successful business continuity. Encouraged by PMDA’s favorable regulatory treatment of the shorter (<30 days) CTN timeline to start first in human studies of candidate products for COVID-19 (https://www.pmda.go.jp/english/int-activities/0001.pdf), we are currently in the preparation process for clinical trials of several novel/repurposed treatments and vaccines. Furthermore, our IRB accommodates the recent MHLW’s request for expedited reviews of applications submitted for COVID-19 trials (https://www.pmda.go.jp/english/int-activities/0002.pdf).

We are both proud and hopeful in our endeavors to contribute to the end of this pandemic.



Sites' Statuses

Fukuoka Site
  • Discussion of New studies: Ongoing
  • IRB meetings: On schedule
  • Site Initiation: Available
  • Screening: Ongoing
  • Subjects visits: Ongoing
  • Monitoring: Ongoing (On-site and Remote Monitoring)
Kumamoto Site
  • Discussion of New studies: Ongoing
  • IRB meetings: On schedule
  • Site Initiation: Available
  • Screening: Ongoing
  • Subjects visits: Ongoing
  • Monitoring: Ongoing (On-site and Remote Monitoring)
Tokyo Site
  • Discussion of New studies: Ongoing
  • IRB meetings: On schedule
  • Site Initiation: Available
  • Screening: Ongoing
  • Subjects visits: Ongoing
  • Monitoring: Ongoing (On-site and Remote Monitoring)